|Coordinate||57,303,079 bp (GRCm38)|
|Base Change||A ⇒ T (forward strand)|
|Gene Name||vav 1 oncogene|
|Chromosomal Location||57,279,100-57,328,031 bp (+)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene is a member of the VAV gene family. The VAV proteins are guanine nucleotide exchange factors (GEFs) for Rho family GTPases that activate pathways leading to actin cytoskeletal rearrangements and transcriptional alterations. The encoded protein is important in hematopoiesis, playing a role in T-cell and B-cell development and activation. The encoded protein has been identified as the specific binding partner of Nef proteins from HIV-1. Coexpression and binding of these partners initiates profound morphological changes, cytoskeletal rearrangements and the JNK/SAPK signaling cascade, leading to increased levels of viral transcription and replication. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Apr 2012]
PHENOTYPE: Homozygous null mutants exhibit defective T cell maturation, interleukin-2 production, and cell cycle progression. Immunoglobulin class switching is also impaired and attributed to defective T cell help. [provided by MGI curators]
|Amino Acid Change||Lysine changed to Stop codon|
|Institutional Source||Beutler Lab|
|Gene Model||predicted gene model for protein(s): [ENSMUSP00000005889] [ENSMUSP00000108491] [ENSMUSP00000126694]|
AA Change: K444*
|Predicted Effect||probably null|
AA Change: K444*
|Predicted Effect||probably null|
AA Change: K420*
|Predicted Effect||probably null|
|Alleles Listed at MGI|
|Mode of Inheritance||Autosomal Recessive|
|Last Updated||2019-01-31 12:58 PM by Diantha La Vine|
|Record Created||2017-08-18 9:39 AM by Bruce Beutler|
The tardive phenotype was identified among N-ethyl-N-nitrosourea (ENU)-mutagenized G3 mice of the pedigree R5503, some of which showed an increase in the B to T cell ratio (Figure 1), an increased in the CD4+ to CD8+ T cell ratio (Figure 2), reduced frequencies of B1 cells (Figure 3), T cells (Figure 4), CD4+ T cells (Figure 5), CD8+ T cells (Figure 6), CD8+ T cells in CD3+ T cells (Figure 7), naive CD4 T cells in CD4 T cells (Figure 8), and naive CD8 T cells in CD8 T cells (Figure 9) with concomitant increased frequencies of central memory CD4 T cells in CD4 T cells (Figure 10), central memory CD8 T cells in CD8 T cells (Figure 11), and effector memory CD4 T cells in CD4 T cells (Figure 12). Expression of IgD on peripheral B cells was reduced (Figure 13), but expression of IgM on peripheral B cells was increased (Figure 14). Expression of CD44 on peripheral T cells (Figure 15), CD4+ T cells (Figure 16), and CD8+ T cells (Figure 17) was increased. The T-dependent antibody response to ovalbumin administered with aluminum hydroxide was also diminished (Figure 18).
|Nature of Mutation|
Whole exome HiSeq sequencing of the G1 grandsire identified 99 mutations. All of the above anomalies were linked by continuous variable mapping to a mutation in Vav1: an A to T transversion at base pair 57,303,079 (v38) on chromosome 17, or base pair 24,001 in the GenBank genomic region NC_000083. The strongest association was found with a recessive model of linkage to the normalized B to T cell ratio, wherein five variant homozygotes departed phenotypically from 18 homozygous reference mice and 24 heterozygous mice with a P value of 3.933 x 10-29 (Figure 19). A substantial semidominant effect was observed in most of the assays but the mutation is preponderantly recessive, and in no assay was a purely dominant effect observed.
The mutation corresponds to residue 1,428 in the mRNA sequence NM_011691 within exon 14 of 27 total exons.
The mutated nucleotide is indicated in red. The mutation results in substitution of lysine 444 for a premature stop codon (K444*) in the VAV1 protein.
Vav1 has several domains, including a calponin-homology (CH) domain, an acidic (Ac) motif, a DBL homology (DH) domain, a pleckstrin homology (PH) domain, a phorbol-ester/DAG-type zinc finger (alternatively, C1 domain), a proline-rich region, a Src homology 2 (SH2) domain, and two Src homology 3 (SH3) domains [PDB: 3KY9; (1;2); reviewed in (3)]. Vav1 also has two nuclear localization sequences. The functions of the Vav1 domains are detailed, below.
Each of the Vav1 domains has a unique function. The exact function of the CH domain of Vav1 is unknown; however, it is associated with the induction of calcium release putatively by promoting the activation of phospholipase C-γ (PLCγ; see the record for queen) (4). Several proteins interact with the CH domain (Table 1), but it is unknown if any of these proteins promote Vav1-associated calcium release (5;6). The Ac motif contains three regulatory tyrosines: Tyr142, Tyr160, and Tyr174 (in mouse). Tyr174 binds the GTPase interaction pocket of the DH domain to control the guanine exchange factor (GEF) activity of Vav1 towards the Rho family GTPases Rac1, Rac2 (see the record for bingo), Cdc42, and RhoA . Phosphorylation of Tyr174 after receptor stimulation releases it from the binding pocket and alleviates the autoinhibition (2;7). The DH domain of Vav1 facilitates its GEF activity (8). The PH domain interacts with polyphosphoinositides, promoting Vav1 localization to the plasma membrane and regulation of its GEF activity (9;10). The ZF/C1, proline-rich, SH2, and SH3 domains all mediate protein-protein interactions (Table 1) (9). The outcomes of most of the protein-protein interactions are unknown, but many promote Vav1 function in multiple signaling pathways.
Table 1. Vav1 interacting proteins
The tardive mutation results in substitution of lysine 444 for a premature stop codon (K444*) in the VAV1 protein; amino acid 444 is within the PH domain.
Vav1 is only expressed in hematopoietic tissues, including spleen, thymus, lymph nodes, and bone marrow (1;25). Vav1 is typically localized to the cytoplasm, but can translocate to the nucleus to function in transcription (25).
Vav1 expression has also been detected in several human cancers, including neuroblastomas (27), pancreatic ductal adenocarcinoma (28), lung cancer (29), breast cancer (30), ovarian cancer, prostate cancer (31), medulloblastomas (32), and B-CLL (33).
Vav1 is a guanine nucleotide exchange factor (GEF) for Rho family GTPases. Vav1 is essential for hematopoiesis, including T- and B-cell development and activation (34-36). Vav1 also functions in the adhesion, migration, and phagocytosis of mature hematopoietic cells by regulating cytoskeletal rearrangement [reviewed in (37)]. In NK cells, the Vav1 GEF activity is required for activation of NK-associated killing (38). Vav1 has several functions in macrophages, including Rac-dependent complement-mediated phagocytosis (39), cell migration (40), and chemotaxis to CSF-1 (41).
Vav1 functions downstream of several immune receptors, including the T-cell receptor (TCR) (42), B-cell receptor (BCR) (43), natural killer (NK) receptors (44), FcRI (45), cytokine receptors (46), chemokine receptors (47), and integrins (48). The function of Vav1 in TCR and BCR-associated signaling is described in more detail, below.
In T cell receptor-associated signaling, ligand binding promotes the recruitment of the tyrosine kinases Lck (see the record for Lemon) and Fyn to the receptor complex. CD45 dephosphorylates C-terminal inhibitory tyrosine residues on Lck and Fyn, thereby promoting the activation of Lck and Fyn. Once activated, they phosphorylate ITAMS present on the CD3 and ζ chains. Phosphorylation of the ITAM motifs results in recruitment of ZAP-70 and Syk, which trans- and auto-phosphorylate to form binding sites for SH2 domain- and protein tyrosine binding domain-containing proteins. The Syk family kinases phosphorylate LAT and SLP-76. LAT binds to the adaptor proteins growth factor receptor-bound 2 (Grb2), Src homologous and collagen (Shc) and GRB2-related adaptor downstream of Shc (Gads), as well as phosphatidylinositol 3-kinase (PI3K) and PLC-γ1. SLP-76 binds Vav1, Nck (non-catalytic region of tyrosine kinase adaptor protein), IL-2-induced tyrosine kinase (Itk; see the record for itxaro), PLC-γ1, adhesion and degranulation-promoting adaptor protein (ADAP), and hematopoietic progenitor kinase 1 (HPK1) after Syk-mediated SLP-76 phosphorylation. This proximal signaling complex is required for PLC-γ1-dependent pathways including calcium (Ca2+) mobilization and diacylglycerol (DAG)-induced responses, cytoskeleton rearrangements, and integrin activation pathways. In B cell receptor-mediated signaling, the recruitment of Vav1, Nck, and Ras by BLNK to the BCR activates MAP kinase cascades such as JNK, p38 and extracellular signal regulated kinase (ERK). Together, these signals allow the activation of multiple transcription factors, including nuclear factor of activated T cells (NF-AT), NF-κB (see the records for puff, xander and panr2) and AP-1, which subsequently regulate biological responses including cell proliferation, differentiation, and apoptosis as well as the secretion of antigen-specific antibodies.
Following BCR ligation, Blk and/or Lyn phosphorylates the ITAMs of the Igα (see the record for crab)/Igβ BCR subunits (49;50). These phosphotyrosines then act as docking sites for the SH2 domains of Syk, resulting in Syk phosphorylation and activation. Syk phosphorylates a number of downstream targets including BLNK, PLCγ2, and protein kinase C β (PKCβ; see the record for Untied). Phosphorylated BLNK also provides docking sites for Btk, as well as PLCγ2, which results in the additional phosphorylation and activation of PLCγ2 by Btk leading to the hydrolysis of phosphatidylinositol-3,4-diphosphate (PIP2) to inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (51). The recruitment of Vav1, Nck, and Ras by BLNK to the BCR activates MAP kinase cascades such as JNK, p38 and extracellular signal regulated kinase (ERK) [reviewed in (52)]. Together, these signals allow the activation of multiple transcription factors, including nuclear factor of activated T cells (NF-AT), NF-κB (see the records for finlay, xander and panr2) and AP-1, which subsequently regulate biological responses including cell proliferation, differentiation, and apoptosis as well as the secretion of antigen-specific antibodies [reviewed in (53)].
Vav1 is a binding partner of Nef proteins from HIV-1 (54). Binding of VAV1 and Nef results in morphological changes, cytoskeletal rearrangements, and activation of the JNK/SAPK signaling cascade, subsequently leading to increased viral transcription and replication.
Vav1 putatively functions in malignancies, including neuroblastoma, melanoma, pancreatic tumors and B-cell chronic lymphocytic leukemia. Patients with Vav1-positive tumors had a worse prognosis than patients with Vav1-negative tumors (28). High amounts of nuclear Vav1 in early invasive breast tumors were positively correlated with a low incidence of relapse (31). The link between Vav1 and cancer is unclear, but it has been attributed to its GEF activity towards Rho/RacGTPases, which regulate cytoskeleton organization, gene transcription, cell proliferation, migration, growth, and survival (55;56). Additional links between Vav1 and cancer include Vav1-stimulated MAPK signaling, Vav1-regulated growth factor (e.g., CSF-1) expression (57), Vav1-associated cell cycle progression and gene transcription, Vav1-associated synergistic signaling cross-talk between cancer cells and the tumor microenvironment (58), and Vav1-stimulated autocrine ligand secretion (59).
In the nucleus, Vav1 interacts with components of the DNA-dependent protein kinase complex and with hnRNP proteins as part of transcriptionally active complexes (60-62).
Vav1-deficient (Vav1-/-) mice exhibited embryonic lethality between embryonic day (E) 3.5 and E7.5 (63). A second Vav1-/- mouse model was viable, and exhibited impaired negative T cell selection (64). Single-positive (namely CD4+ T cells), double-positive, and double-negative T cell numbers as well as the number of mature B cells and B1 cells were reduced in the Vav1-/- mice (65-70). T cells from the Vav1-/- mice showed reduced proliferative responses to anti-CD3 stimulation as well as reduced T cell receptor-induced calcium fluxes (64;66;67). The T-dependent IgG response to VSV infection and to NIP-OVA was reduced (70). Homozygous mice expressing an ENU-induced Vav1 allele (F203S) exhibited increased numbers of T cells after immunization (MGI; accessed September 14, 2017).
tardive(F):5'- GGTTAAGGTTAGGATGCGAACC -3'
tardive(R):5'- AGGCTGTCTAGACCATCCAAAC -3'
tardive_seq(F):5'- GTTAGGATGCGAACCCACAGC -3'
tardive_seq(R):5'- GAGGTTGCCTCTGAACTCTAAC -3'
1. Katzav, S., Martin-Zanca, D., and Barbacid, M. (1989) Vav, a Novel Human Oncogene Derived from a Locus Ubiquitously Expressed in Hematopoietic Cells. EMBO J. 8, 2283-2290.
2. Yu, B., Martins, I. R., Li, P., Amarasinghe, G. K., Umetani, J., Fernandez-Zapico, M. E., Billadeau, D. D., Machius, M., Tomchick, D. R., and Rosen, M. K. (2010) Structural and Energetic Mechanisms of Cooperative Autoinhibition and Activation of Vav1. Cell. 140, 246-256.
3. Katzav, S. (2009) Vav1: A Hematopoietic Signal Transduction Molecule Involved in Human Malignancies. Int J Biochem Cell Biol. 41, 1245-1248.
4. Cao, Y., Janssen, E. M., Duncan, A. W., Altman, A., Billadeau, D. D., and Abraham, R. T. (2002) Pleiotropic Defects in TCR Signaling in a Vav-1-Null Jurkat T-Cell Line. EMBO J. 21, 4809-4819.
5. Tybulewicz, V. L. (2005) Vav-Family Proteins in T-Cell Signalling. Curr Opin Immunol. 17, 267-274.
6. Zhou, Z., Yin, J., Dou, Z., Tang, J., Zhang, C., and Cao, Y. (2007) The Calponin Homology Domain of Vav1 Associates with Calmodulin and is Prerequisite to T Cell Antigen Receptor-Induced Calcium Release in Jurkat T Lymphocytes. J Biol Chem. 282, 23737-23744.
7. Aghazadeh, B., Lowry, W. E., Huang, X. Y., and Rosen, M. K. (2000) Structural Basis for Relief of Autoinhibition of the Dbl Homology Domain of Proto-Oncogene Vav by Tyrosine Phosphorylation. Cell. 102, 625-633.
8. Movilla, N., Dosil, M., Zheng, Y., and Bustelo, X. R. (2001) How Vav Proteins Discriminate the GTPases Rac1 and RhoA from Cdc42. Oncogene. 20, 8057-8065.
9. Rapley, J., Tybulewicz, V. L., and Rittinger, K. (2008) Crucial Structural Role for the PH and C1 Domains of the Vav1 Exchange Factor. EMBO Rep. 9, 655-661.
10. Das, B., Shu, X., Day, G. J., Han, J., Krishna, U. M., Falck, J. R., and Broek, D. (2000) Control of Intramolecular Interactions between the Pleckstrin Homology and Dbl Homology Domains of Vav and Sos1 Regulates Rac Binding. J Biol Chem. 275, 15074-15081.
11. De Sepulveda, P., Ilangumaran, S., and Rottapel, R. (2000) Suppressor of Cytokine Signaling-1 Inhibits VAV Function through Protein Degradation. J Biol Chem. 275, 14005-14008.
12. Hobert, O., Jallal, B., and Ullrich, A. (1996) Interaction of Vav with ENX-1, a Putative Transcriptional Regulator of Homeobox Gene Expression. Mol Cell Biol. 16, 3066-3073.
13. Groysman, M., Russek, C. S., and Katzav, S. (2000) Vav, a GDP/GTP Nucleotide Exchange Factor, Interacts with GDIs, Proteins that Inhibit GDP/GTP Dissociation. FEBS Lett. 467, 75-80.
14. Katzav, S., Sutherland, M., Packham, G., Yi, T., and Weiss, A. (1994) The Protein Tyrosine Kinase ZAP-70 can Associate with the SH2 Domain of Proto-Vav. J Biol Chem. 269, 32579-32585.
15. Darby, C., Geahlen, R. L., and Schreiber, A. D. (1994) Stimulation of Macrophage Fc Gamma RIIIA Activates the Receptor-Associated Protein Tyrosine Kinase Syk and Induces Phosphorylation of Multiple Proteins Including p95Vav and p62/GAP-Associated Protein. J Immunol. 152, 5429-5437.
16. Wu, J., Motto, D. G., Koretzky, G. A., and Weiss, A. (1996) Vav and SLP-76 Interact and Functionally Cooperate in IL-2 Gene Activation. Immunity. 4, 593-602.
17. Johmura, S., Oh-hora, M., Inabe, K., Nishikawa, Y., Hayashi, K., Vigorito, E., Kitamura, D., Turner, M., Shingu, K., Hikida, M., and Kurosaki, T. (2003) Regulation of Vav Localization in Membrane Rafts by Adaptor Molecules Grb2 and BLNK. Immunity. 18, 777-787.
18. Ye, Z. S., and Baltimore, D. (1994) Binding of Vav to Grb2 through Dimerization of Src Homology 3 Domains. Proc Natl Acad Sci U S A. 91, 12629-12633.
19. Hobert, O., Schilling, J. W., Beckerle, M. C., Ullrich, A., and Jallal, B. (1996) SH3 Domain-Dependent Interaction of the Proto-Oncogene Product Vav with the Focal Contact Protein Zyxin. Oncogene. 12, 1577-1581.
20. Hobert, O., Jallal, B., Schlessinger, J., and Ullrich, A. (1994) Novel Signaling Pathway Suggested by SH3 Domain-Mediated p95vav/heterogeneous Ribonucleoprotein K Interaction. J Biol Chem. 269, 20225-20228.
21. Lazer, G., Pe'er, L., Schapira, V., Richard, S., and Katzav, S. (2007) The Association of Sam68 with Vav1 Contributes to Tumorigenesis. Cell Signal. 19, 2479-2486.
22. Houlard, M., Romero-Portillo, F., Germani, A., Depaux, A., Regnier-Ricard, F., Gisselbrecht, S., and Varin-Blank, N. (2005) Characterization of VIK-1: A New Vav-Interacting Kruppel-Like Protein. Oncogene. 24, 28-38.
23. Razidlo, G. L., Wang, Y., Chen, J., Krueger, E. W., Billadeau, D. D., and McNiven, M. A. (2013) Dynamin 2 Potentiates Invasive Migration of Pancreatic Tumor Cells through Stabilization of the Rac1 GEF Vav1. Dev Cell. 24, 573-585.
24. Rauch, S., Pulkkinen, K., Saksela, K., and Fackler, O. T. (2008) Human Immunodeficiency Virus Type 1 Nef Recruits the Guanine Exchange Factor Vav1 Via an Unexpected Interface into Plasma Membrane Microdomains for Association with p21-Activated Kinase 2 Activity. J Virol. 82, 2918-2929.
25. Bustelo, X. R. (2000) Regulatory and Signaling Properties of the Vav Family. Mol Cell Biol. 20, 1461-1477.
26. Turner, M., and Billadeau, D. D. (2002) VAV Proteins as Signal Integrators for Multi-Subunit Immune-Recognition Receptors. Nat Rev Immunol. 2, 476-486.
27. Hornstein, I., Pikarsky, E., Groysman, M., Amir, G., Peylan-Ramu, N., and Katzav, S. (2003) The Haematopoietic Specific Signal Transducer Vav1 is Expressed in a Subset of Human Neuroblastomas. J Pathol. 199, 526-533.
28. Fernandez-Zapico, M. E., Gonzalez-Paz, N. C., Weiss, E., Savoy, D. N., Molina, J. R., Fonseca, R., Smyrk, T. C., Chari, S. T., Urrutia, R., and Billadeau, D. D. (2005) Ectopic Expression of VAV1 Reveals an Unexpected Role in Pancreatic Cancer Tumorigenesis. Cancer Cell. 7, 39-49.
29. Lazer, G., Idelchuk, Y., Schapira, V., Pikarsky, E., and Katzav, S. (2009) The Haematopoietic Specific Signal Transducer Vav1 is Aberrantly Expressed in Lung Cancer and Plays a Role in Tumourigenesis. J Pathol. 219, 25-34.
30. Sebban, S., Farago, M., Gashai, D., Ilan, L., Pikarsky, E., Ben-Porath, I., and Katzav, S. (2013) Vav1 Fine Tunes p53 Control of Apoptosis Versus Proliferation in Breast Cancer. PLoS One. 8, e54321.
31. Grassilli, S., Brugnoli, F., Lattanzio, R., Rossi, C., Perracchio, L., Mottolese, M., Marchisio, M., Palomba, M., Nika, E., Natali, P. G., Piantelli, M., Capitani, S., and Bertagnolo, V. (2014) High Nuclear Level of Vav1 is a Positive Prognostic Factor in Early Invasive Breast Tumors: A Role in Modulating Genes Related to the Efficiency of Metastatic Process. Oncotarget. 5, 4320-4336.
32. Lindsey, J. C., Kawauchi, D., Schwalbe, E. C., Solecki, D. J., Selby, M. P., McKinnon, P. J., Olson, J. M., Hayden, J. T., Grundy, R. G., Ellison, D. W., Williamson, D., Bailey, S., Roussel, M. F., and Clifford, S. C. (2015) Cross-Species Epigenetics Identifies a Critical Role for VAV1 in SHH Subgroup Medulloblastoma Maintenance. Oncogene. 34, 4746-4757.
33. Prieto-Sanchez, R. M., Hernandez, J. A., Garcia, J. L., Gutierrez, N. C., San Miguel, J., Bustelo, X. R., and Hernandez, J. M. (2006) Overexpression of the VAV Proto-Oncogene Product is Associated with B-Cell Chronic Lymphocytic Leukaemia Displaying Loss on 13q. Br J Haematol. 133, 642-645.
34. Turner, M., Mee, P. J., Walters, A. E., Quinn, M. E., Mellor, A. L., Zamoyska, R., and Tybulewicz, V. L. (1997) A Requirement for the Rho-Family GTP Exchange Factor Vav in Positive and Negative Selection of Thymocytes. Immunity. 7, 451-460.
35. Arana, E., Vehlow, A., Harwood, N. E., Vigorito, E., Henderson, R., Turner, M., Tybulewicz, V. L., and Batista, F. D. (2008) Activation of the Small GTPase Rac2 Via the B Cell Receptor Regulates B Cell Adhesion and Immunological-Synapse Formation. Immunity. 28, 88-99.
36. Krawczyk, C., Oliveira-dos-Santos, A., Sasaki, T., Griffiths, E., Ohashi, P. S., Snapper, S., Alt, F., and Penninger, J. M. (2002) Vav1 Controls Integrin Clustering and MHC/peptide-Specific Cell Adhesion to Antigen-Presenting Cells. Immunity. 16, 331-343.
37. Bertagnolo, V., Brugnoli, F., Grassilli, S., Nika, E., and Capitani, S. (2012) Vav1 in Differentiation of Tumoral Promyelocytes. Cell Signal. 24, 612-620.
38. Billadeau, D. D., Brumbaugh, K. M., Dick, C. J., Schoon, R. A., Bustelo, X. R., and Leibson, P. J. (1998) The Vav-Rac1 Pathway in Cytotoxic Lymphocytes Regulates the Generation of Cell-Mediated Killing. J Exp Med. 188, 549-559.
39. Hall, A. B., Gakidis, M. A., Glogauer, M., Wilsbacher, J. L., Gao, S., Swat, W., and Brugge, J. S. (2006) Requirements for Vav Guanine Nucleotide Exchange Factors and Rho GTPases in FcgammaR- and Complement-Mediated Phagocytosis. Immunity. 24, 305-316.
40. Wells, C. M., Bhavsar, P. J., Evans, I. R., Vigorito, E., Turner, M., Tybulewicz, V., and Ridley, A. J. (2005) Vav1 and Vav2 Play Different Roles in Macrophage Migration and Cytoskeletal Organization. Exp Cell Res. 310, 303-310.
41. Vedham, V., Phee, H., and Coggeshall, K. M. (2005) Vav Activation and Function as a Rac Guanine Nucleotide Exchange Factor in Macrophage Colony-Stimulating Factor-Induced Macrophage Chemotaxis. Mol Cell Biol. 25, 4211-4220.
42. Bustelo, X. R., Ledbetter, J. A., and Barbacid, M. (1992) Product of Vav Proto-Oncogene Defines a New Class of Tyrosine Protein Kinase Substrates. Nature. 356, 68-71.
43. Bustelo, X. R., and Barbacid, M. (1992) Tyrosine Phosphorylation of the Vav Proto-Oncogene Product in Activated B Cells. Science. 256, 1196-1199.
44. Galandrini, R., Palmieri, G., Piccoli, M., Frati, L., and Santoni, A. (1999) Role for the Rac1 Exchange Factor Vav in the Signaling Pathways Leading to NK Cell Cytotoxicity. J Immunol. 162, 3148-3152.
45. Manetz, T. S., Gonzalez-Espinosa, C., Arudchandran, R., Xirasagar, S., Tybulewicz, V., and Rivera, J. (2001) Vav1 Regulates Phospholipase Cgamma Activation and Calcium Responses in Mast Cells. Mol Cell Biol. 21, 3763-3774.
46. Evans, G. A., Howard, O. M., Erwin, R., and Farrar, W. L. (1993) Interleukin-2 Induces Tyrosine Phosphorylation of the Vav Proto-Oncogene Product in Human T Cells: Lack of Requirement for the Tyrosine Kinase Lck. Biochem J. 294 ( Pt 2), 339-342.
47. Garcia-Bernal, D., Wright, N., Sotillo-Mallo, E., Nombela-Arrieta, C., Stein, J. V., Bustelo, X. R., and Teixido, J. (2005) Vav1 and Rac Control Chemokine-Promoted T Lymphocyte Adhesion Mediated by the Integrin alpha4beta1. Mol Biol Cell. 16, 3223-3235.
48. Zheng, L., Sjolander, A., Eckerdal, J., and Andersson, T. (1996) Antibody-Induced Engagement of Beta 2 Integrins on Adherent Human Neutrophils Triggers Activation of p21ras through Tyrosine Phosphorylation of the Protooncogene Product Vav. Proc Natl Acad Sci U S A. 93, 8431-8436.
49. Yamamoto, T., Yamanashi, Y., and Toyoshima, K. (1993) Association of Src-Family Kinase Lyn with B-Cell Antigen Receptor. Immunol Rev. 132, 187-206.
50. Saouaf, S. J., Kut, S. A., Fargnoli, J., Rowley, R. B., Bolen, J. B., and Mahajan, S. (1995) Reconstitution of the B Cell Antigen Receptor Signaling Components in COS Cells. J Biol Chem. 270, 27072-27078.
51. Hashimoto, S., Iwamatsu, A., Ishiai, M., Okawa, K., Yamadori, T., Matsushita, M., Baba, Y., Kishimoto, T., Kurosaki, T., and Tsukada, S. (1999) Identification of the SH2 Domain Binding Protein of Bruton's Tyrosine Kinase as BLNK--Functional Significance of Btk-SH2 Domain in B-Cell Antigen Receptor-Coupled Calcium Signaling. Blood. 94, 2357-2364.
52. Koretzky, G. A., Abtahian, F., and Silverman, M. A. (2006) SLP76 and SLP65: Complex Regulation of Signalling in Lymphocytes and Beyond. Nat Rev Immunol. 6, 67-78.
53. Guo, B., Kato, R. M., Garcia-Lloret, M., Wahl, M. I., and Rawlings, D. J. (2000) Engagement of the Human Pre-B Cell Receptor Generates a Lipid Raft-Dependent Calcium Signaling Complex. Immunity. 13, 243-253.
54. Fackler, O. T., Luo, W., Geyer, M., Alberts, A. S., and Peterlin, B. M. (1999) Activation of Vav by Nef Induces Cytoskeletal Rearrangements and Downstream Effector Functions. Mol Cell. 3, 729-739.
55. Cook, D. R., Rossman, K. L., and Der, C. J. (2014) Rho Guanine Nucleotide Exchange Factors: Regulators of Rho GTPase Activity in Development and Disease. Oncogene. 33, 4021-4035.
56. Bouzahzah, B., Albanese, C., Ahmed, F., Pixley, F., Lisanti, M. P., Segall, J. D., Condeelis, J., Joyce, D., Minden, A., Der, C. J., Chan, A., Symons, M., and Pestell, R. G. (2001) Rho Family GTPases Regulate Mammary Epithelium Cell Growth and Metastasis through Distinguishable Pathways. Mol Med. 7, 816-830.
57. Sebban, S., Farago, M., Rabinovich, S., Lazer, G., Idelchuck, Y., Ilan, L., Pikarsky, E., and Katzav, S. (2014) Vav1 Promotes Lung Cancer Growth by Instigating Tumor-Microenvironment Cross-Talk Via Growth Factor Secretion. Oncotarget. 5, 9214-9226.
58. Garcia, J. L., Couceiro, J., Gomez-Moreta, J. A., Gonzalez Valero, J. M., Briz, A. S., Sauzeau, V., Lumbreras, E., Delgado, M., Robledo, C., Almunia, M. L., Bustelo, X. R., and Hernandez, J. M. (2012) Expression of VAV1 in the Tumour Microenvironment of Glioblastoma Multiforme. J Neurooncol. 110, 69-77.
59. Wilsbacher, J. L., Moores, S. L., and Brugge, J. S. (2006) An Active Form of Vav1 Induces Migration of Mammary Epithelial Cells by Stimulating Secretion of an Epidermal Growth Factor Receptor Ligand. Cell Commun Signal. 4, 5-811X-4-5.
60. Houlard, M., Arudchandran, R., Regnier-Ricard, F., Germani, A., Gisselbrecht, S., Blank, U., Rivera, J., and Varin-Blank, N. (2002) Vav1 is a Component of Transcriptionally Active Complexes. J Exp Med. 195, 1115-1127.
61. Romero, F., Dargemont, C., Pozo, F., Reeves, W. H., Camonis, J., Gisselbrecht, S., and Fischer, S. (1996) P95vav Associates with the Nuclear Protein Ku-70. Mol Cell Biol. 16, 37-44.
62. Romero, F., Germani, A., Puvion, E., Camonis, J., Varin-Blank, N., Gisselbrecht, S., and Fischer, S. (1998) Vav Binding to Heterogeneous Nuclear Ribonucleoprotein (hnRNP) C. Evidence for Vav-hnRNP Interactions in an RNA-Dependent Manner. J Biol Chem. 273, 5923-5931.
63. Zmuidzinas, A., Fischer, K. D., Lira, S. A., Forrester, L., Bryant, S., Bernstein, A., and Barbacid, M. (1995) The Vav Proto-Oncogene is Required Early in Embryogenesis but Not for Hematopoietic Development in Vitro. EMBO J. 14, 1-11.
64. Turner, M., Mee, P. J., Walters, A. E., Quinn, M. E., Mellor, A. L., Zamoyska, R., and Tybulewicz, V. L. (1997) A Requirement for the Rho-Family GTP Exchange Factor Vav in Positive and Negative Selection of Thymocytes. Immunity. 7, 451-460.
65. Saveliev, A., Vanes, L., Ksionda, O., Rapley, J., Smerdon, S. J., Rittinger, K., and Tybulewicz, V. L. (2009) Function of the Nucleotide Exchange Activity of vav1 in T Cell Development and Activation. Sci Signal. 2, ra83.
66. Fujikawa, K., Miletic, A. V., Alt, F. W., Faccio, R., Brown, T., Hoog, J., Fredericks, J., Nishi, S., Mildiner, S., Moores, S. L., Brugge, J., Rosen, F. S., and Swat, W. (2003) Vav1/2/3-Null Mice Define an Essential Role for Vav Family Proteins in Lymphocyte Development and Activation but a Differential Requirement in MAPK Signaling in T and B Cells. J Exp Med. 198, 1595-1608.
67. Prisco, A., Vanes, L., Ruf, S., Trigueros, C., and Tybulewicz, V. L. (2005) Lineage-Specific Requirement for the PH Domain of Vav1 in the Activation of CD4+ but Not CD8+ T Cells. Immunity. 23, 263-274.
68. Raberger, J., Boucheron, N., Sakaguchi, S., Penninger, J. M., and Ellmeier, W. (2008) Impaired T-Cell Development in the Absence of Vav1 and Itk. Eur J Immunol. 38, 3530-3542.
69. Fischer, K. D., Kong, Y. Y., Nishina, H., Tedford, K., Marengere, L. E., Kozieradzki, I., Sasaki, T., Starr, M., Chan, G., Gardener, S., Nghiem, M. P., Bouchard, D., Barbacid, M., Bernstein, A., and Penninger, J. M. (1998) Vav is a Regulator of Cytoskeletal Reorganization Mediated by the T-Cell Receptor. Curr Biol. 8, 554-562.
|Science Writers||Anne Murray|
|Authors||Xue Zhong, Jin Huk Choi, and Bruce Beutler|